Douglas M. Schirle
Analyst · Anthology Capital
For the second quarter ended September 30, 2013, we reported net income of $386,000 or $0.01 per diluted share and net revenues of $15.5 million compared to net income of $1.1 million or $0.04 per diluted share and net revenues of $16.0 million in the fiscal quarter ended September 30, 2012. In the prior quarter ended June 30, 2013, we reported net loss of $441,000 or $0.02 per diluted share and net revenues of $16.4 million. Second quarter direct and indirect sales to Cisco Systems were $3.4 million or 22.2% of net revenues compared to $2.8 million or 17.1% of net revenues in the prior quarter and $4.9 million or 30.6% of net revenues in the same period a year ago. Sales to Alcatel-Lucent were $3.2 million or 20.4% of net revenues during the quarter. Military/defense sales were 12.3% of shipments compared to 13.3% of shipments in the prior quarter and 7.4% of shipments in the comparable period a year ago. SigmaQuad sales were 42.3% of shipments compared to 41.6% in the prior quarter and 33.9% in the second quarter of fiscal 2013. Second quarter fiscal 2014 operating income was $241,000 or 1.6% of net revenues compared to an operating loss of $541,000 in the prior quarter and operating income of $1.5 million or 9.4% of net revenue a year ago. Total operating expenses in the second quarter fiscal quarter of 2014 was $7.2 million, up from $5.7 million in the second quarter of fiscal 2013, down from $8 million in the second quarter -- in the first quarter. Research and development expense was relatively unchanged at $3 million compared to $3 million in the prior quarter and $2.9 million in the prior year period. Selling, general and administrative expenses, which include the litigation-related expenses, were up substantially year-over-year to $4.2 million compared to $2.8 million in the fiscal quarter ended September 30, 2012, but down sequentially from $5 million in the prior quarter. Included in SG&A during these periods, respectively, was $1.7 million, $300,000 and $2.3 million in litigation-related expenses. Total second quarter pretax stock-based compensation expense was $563,000 compared to $565,000 in the prior quarter and $560,000 in the comparable quarter a year ago. At September 30, 2013, we had $75 million in cash, cash equivalents and short-term investments, $34.6 million in long-term investments, $91.6 million in working capital, no debt and stockholders' equity of $135.6 million. Accounts payable at September 30, 2013, was $3.7 million compared to $3.8 million at March 31, 2013. Net inventories was $11.2 million at September 30, 2013, down from $13.8 million at March 31, 2013, down from $12.2 million at the end of the prior quarter. Inventory turns at September 30, 2013, were 2.9x compared to 2.4x at March 31, 2013. Depreciation and amortization expense was $504,000 for the quarter. Looking forward to the third quarter, we currently expect net revenues to be in the range of $14 million to $15 million, with gross margin of approximately 44%. We also expect the ongoing legal expenses related to the patent litigation and antitrust litigation will continue to affect our operating income and our bottom line. These expenses are difficult to forecast. We currently estimate that they will be approximately $1.7 million in the third quarter. Operating expenses in total is expected to be approximately $8.8 million, which include approximately $1.3 million in total related to R&D mass sets, one for the 288-megabyte device, which will be our first 40-nanometer tape-out, and the second for next-generation LLDRAM device, in addition to the estimated litigation-related expenses of $1.7 million. Operator, at this point, we'll open the call to Q&A.